A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

Clinical trial NCT07619820 · RECRUITING

Trial details

NCT number: NCT07619820
Sponsor: CSL Behring
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

End Stage Kidney Disease (ESKD)

Start date: 2026-06-17
Primary completion: 2027-08-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.